In recent years, the use of various types of immunotherapy, particularly immune checkpoint inhibitors (ICIs) targeting programmed cell death 1 (PD-1) or programmed death ligand 1 (PD-L1), has revolutionized the treatment of NSCLC [3, 4]. Here, CD274 is linked to non-small cell lung carcinoma.